Related Experiment Video

Updated: Jul 26, 2026

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Antagonistic activity of tiotidine and ranitidine on guinea-pig and rabbit atria

C Kilpatrick, M J Hughes, K E Light

    European Journal of Pharmacology
    |November 12, 1986
    PubMed

    Keywords:
    H2-receptor antagonistscardiac chronotropic responsepharmacological inhibitionatrial tissue studies

    More Related Videos

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation08:56

    Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

    Published on: September 24, 2021

    Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats05:12

    Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

    Published on: February 14, 2022

    Related Concept Videos

    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...